Major growth partnership with Probi

07 July 2021
Major growth partnership with leading global probiotics company Probi
Blis Technologies Limited (NZX:BLT) today announced the formation of a long term strategic
partnership with Probi AB (PROB.STOE), a global company based in Sweden, expected to deliver
significant growth opportunities for Blis.
Key terms
• Establishment of a licence and supply agreement under which Blis has granted Probi rights to
manufacture and sell BLIS K12™ and BLIS M18™, leveraging their established global customer
base.
• Cash issue of $9.18m of new shares to Probi resulting in a 13% strategic shareholding (post
issue), and providing the company with capital to support Blis’ revenue growth initiatives.
• Collaboration in R&D to leverage joint strengths in probiotic innovation to build product
innovation pipeline.
• Appointment of the Probi CEO to the Blis board, post 2021 annual meeting of shareholders.

Transaction overview
Blis has agreed to enter into a long-term strategic partnership with Nasdaq Stockholm-listed Probi, a
global leader in probiotic innovation with strong presence in Europe and USA and growing presence
across Asia Pacific.
Blis Chairman Tony Offen said “This is an exciting opportunity for our company and a significant
endorsement of Blis. Probi provides extensive international industry experience and relationships,
which will drive collaboration opportunities and revenue growth.”
Tom Rönnlund, CEO of Probi says “This is a compelling business partnership for Probi, since Blis is an
innovative, science-led company with leading market share in probiotic oral health. Through this
partnership, we will broaden our portfolio and strengthen our position as leaders in the use of
clinically documented bacterial strains. Beyond immediate commercial opportunities, this strategic
partnership also includes research collaboration to leverage off each other’s strengths”.
$9.18m will be raised from the placement of shares at a price that is a 5% discount to the VWAP for
the 20 trading days to 5 July 2021. Settlement is expected by 8 July 2021.
“Probi’s investment recognises the value of Blis’ probiotic innovation and allows us to further
accelerate our investment in new market and product growth initiatives, along with new product
development to strengthen our pipeline of breakthrough probiotic solutions.” Blis Chief Executive
Brian Watson commented.


Ends

Blis Technologies Limited: 81 Glasgow Street, South Dunedin 9012, PO Box 2208, Dunedin 9012, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz


For further information, please contact:

Brian Watson
CEO
+64 27 705 9133


About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand
and in Australia, Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at
www.blis.co.nz.

Website: www.unconditionalskin.com
Instagram: @unconditionalskin #BLISQ24 #USC
Facebook: @unconditionalskin


About Probi
Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics
for supplements and functional food. We are experts at managing stable, live bacteria from R&D through
every stage of the manufacturing process and are dedicated to making the health-enhancing benefits of
probiotics available to people everywhere. Our health concepts, formulations, and formats are supported
by robust clinical documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has
expanded its operations to more than 40 markets. We hold more than 400 patents globally. Read more at
www.probi.com. Probi® is a registered trademark of Probi AB.